Research fellow

Prof. Dr. Ulrike Haug

Curriculum vitae

Education and academic positions
  • Since 2015 Professor of Clinical Epidemiology and Pharmacoepidemiology at the University of Bremen and Head of the Department Clinical Epidemiology at the Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany
  • 2010-2015 Group Leader, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • 03/2013 Habilitation and Venia Legendi for Epidemiology at the Medical Faculty of the Ruprecht-Karls-University of Heidelberg
  • 2008-2009 Visiting Assistant Research Professor, Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, USA
  • 2006-2010 Postdoctoral Research Fellow, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • 07/2006 PhD in Epidemiology, University of Heidelberg
  • 2002-2005 PhD program in Epidemiology (DFG-funded Graduiertenkolleg 793), German Centre for Research on Ageing, Heidelberg, Germany
  • 01/2003 Approbation as Pharmacist
  • 2001-2002 Working in a pharmacy (Heidelberg) and pharmaceutical industry (Karlsruhe) for accreditation as Pharmacist
  • 1997-2001 Study of Pharmacy at the University of Wurzburg, Germany
Professional activities
  • Since 2020 Selected as a CORE member of the ISPE RWE Task Force: RWE and Oncology Subgroup
  • Since 2019 Elected member of the Scientific Council of the International Agency for Research on Cancer (IARC)
  • Since 2019 Invited member of the expert committee “Cancer Prevention” of the National Decade Against Cancer
  • Since 2018 Head of expert group “Medication and Pharmacoepidemiology” of the German National Cohort (NAKO)
  • Since 2018 Section editor “Pharmacoepidemiology” of the journal Current Epidemiology Reports
  • Since 2018 Invited member and deputy chair of the advisory board of the German Centre for Cancer Registry Data (ZFKD) at the Robert Koch Institute
  • Since 2017 Invited member of the expert advisory board of the foundation “Stiftung LebensBlicke”
  • Since 2016 Invited member of the expert committee “Early cancer detection” of the German Cancer Aid
  • Since 2016 Member of the data and safety monitoring board of the European Polyp Surveillance (EPOS) trials
  • Since 2016 Mentor in mentoring programs of the University of Düsseldorf and the University of Würzburg
  • 2015 Consultant to the Ministry of Health of the Grand Duchy of Luxembourg on the establishment of an organized colon cancer screening program
  • Since 2015 Invited member of the international expert working group “Right-sided lesions and interval colorectal cancer” (World Endoscopy Organization)
  • Since 2012 Invited member of the international expert working group “Development and evaluation of new tests for colorectal cancer screening” (World Endoscopy Organization)
  • Since 2012 Reviewer for national and international funding organizations (e.g. German Research Foundation, The Netherlands Organization for Health Research and Development)


Research interests

  • Epidemiology of colorectal carcinoma, colorectal cancer screening, cancer prevention in risk groups, pharmacoepidemiology



Selected publications

  • Articles with peer-review

  • Heinig M, Schwarz S, Haug U. Self-selection for mammography screening according to use of hormone replacement therapy: A systematic literature review. Cancer Epidemiology. 2021;71(Part A):101812.
  • Schäfer W, Reinders T, Riedel O, Haug U. How often are antidepressants prescribed off-label among older adults in Germany? A claims data analysis. British Journal of Clinical Pharmacology. 2021;87(4):1778-1789.
  • Beyerle J, Holowatyj AN, Haffa M, Frei E, Gigic B, Schrotz-King P, Böhm J, Habermann N, Stiborova M, Scherer D, Koelsch T, Skender S, Becker N, Herpel E, Schneider M, Ulrich A, Schirmacher P, Chang-Claude J, Brenner H, Hoffmeister M, Haug U, Owen RW, Ulrich CM. Expression patterns of xenobiotic-metabolizing enzymes in tumor and adjacent normal mucosa tissues among patients with colorectal cancer: The ColoCare Study. Cancer Epidemiology, Biomarkers & Prevention. 2020;29(2):460-469.
  • Haug U, Coupé VMH. The cumulative false-positive rate in colorectal cancer screening: A Markov analysis. European Journal of Gastroenterology and Hepatology. 2020;32(5):575-580.
  • Langner I, Riedel O, Czwikla J, Heinze F, Rothgang H, Zeeb H, Haug U. Linkage of routine data to other data sources in Germany: A practical example illustrating challenges and solutions. Das Gesundheitswesen. 2020;82(Suppl. 2):S117-S121.
  • Pisa F, Reinold J, Kollhorst B, Haug U, Schink T. Individual antidepressants and the risk of fractures in older adults: A new user active comparator study. Clinical Epidemiology. 2020;12:667-678.
  • Schink T, Wentzell N, Dathe K, Onken M, Haug U. Estimating the beginning of pregnancy in German claims data: Development of an algorithm with a focus on the expected delivery date. Frontiers in Public Health. 2020;8:350.
  • Scholle O, Kollhorst B, Haug U. Are prescribers not aware of cardiovascular contraindications for diclofenac? A claims data analysis. Journal of Internal Medicine. 2020;287(2):171-179.
  • Buskermolen M, Cenin DR, Helsingen LM, Guyatt G, Vandvik PO, Haug U, Bretthauer M, Lansdorp-Vogelaar I. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: A microsimulation modelling study. The BMJ. 2019;367:l5383.
  • Langner I, Haug U, Scholle O, Lindemann C, Schröder C, Riedel O. Potential explanations for increasing methylphenidate use in children and adolescents with attention-deficit/hyperactivity disorder in Germany from 2004 to 2013. Journal of Clinical Psychopharmacology. 2019;39(1):39-45.
  • Langner I, Ohlmeier C, Haug U, Hense H-W, Czwikla J, Zeeb H. Implementation of an algorithm for the identification of breast cancer deaths in German health insurance claims data: A validation study based on a record linkage with administrative mortality data. BMJ Open. 2019;9:e026834.
  • Langner I, Ohlmeier C, Zeeb H, Haug U, Riedel O. Individual mortality information in the German Pharmacoepidemiological Research Database (GePaRD): A validation study using a record linkage with a large cancer registry. BMJ Open. 2019;9:e028223.
  • Oppelt KA, Luttmann S, Kraywinkel K, Haug U. Incidence of advanced colorectal cancer in Germany: Comparing claims data and cancer registry data. BMC Medical Research Methodology. 2019;19:142.
  • Overbeek J, Kuiper J, van der Heijden A, Labots M, Haug U, Herings R, Nijpels G. Sex- and site-specific differences in colorectal cancer risk among people with type 2 diabetes. International Journal of Colorectal Disease. 2019;34(2):269-276.
  • Pisa F, Reinold J, Kollhorst B, Haug U, Schink T. Antidepressants and the risk of traumatic brain injury in the elderly: Differences between individual agents. Clinical Epidemiology. 2019;11:185-196.
  • Bauer A, Riemann JF, Seufferlein T, Reinshagen M, Hollerbach S, Haug U, Unverzagt S, Boese S, Ritter-Herschbach M, Jahn P, Frese T, Harris M, Landenberger M. Invitation to screening colonoscopy in the population at familial risk for colorectal cancer: A cluster-randomized study aimed at increasing participation rates. Deutsches Ärzteblatt International. 2018;115(43):715-722.
  • Czwikla J, Giersiepen K, Langner I, Enders D, Heinze F, Rothgang H, Haug U, Zeeb H, Hense H-W. A cohort study of mammography screening finds that comorbidity measures are insufficient for controlling selection bias. Journal of Clinical Epidemiology. 2018;104:1-7.
  • Haug U. Aktueller Stand der Evidenz und Entwicklung der Darmkrebsfrüherkennung in Deutschland. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2018;61(12):1513-1516.
  • Haug U, Langner I, Zeeb H. Evaluation von organisierten Programmen zur Krebsfrüherkennung: Allgemeine Aspekte und aktueller Stand in Deutschland. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2018;61(12):1500-1504.
  • Haug U, Riedel O, Cholmakow-Bodechtel C, Olsson L. First-degree relatives of cancer patients: A target group for primary prevention? A cross-sectional study. British Journal of Cancer. 2018;118(9):1255-1261.
  • Oppelt KA, Haug U. Schmerztherapie bei Darmkrebspatienten - Längsschnittanalysen auf Versichertendaten basierend. Der Onkologe. 2018;24(11):848-860.
  • Plath J, Siebenhofer A, Haug U, Koné I, Hechtner M, Blumenstein I, Schulz-Rothe S, Gerlach FM, Guethlin C. Utilization of colonoscopy and colonoscopic findings among individuals aged 40-54 years with a positive family history of colorectal cancer: A cross-sectional study in general practice. European Journal of Cancer Prevention. 2018;27(6):539-545.
  • Rutter MD, Beintaris I, Valori R, Chiu HM, Corley D, Dekker E, Forsberg A, Freixas MC, Gore-Booth J, Haug U, Kaminski MF, Matsuda T, Meijer GA, Morris E, Plumb A, Rabeneck L, Robertson D, Schoen R, Singh H, Tinmouth J, Young G, Sanduleanu S. World Endoscopy Organization consensus statements on post-colonoscopy and post-imaging colorectal cancer. Gastroenterology. 2018;155(3):909-925.e3.
  • Wentzell N, Haug U, Schink T, Engel S, Liebentraut J, Linder R, Onken M, Schaefer C, Dathe K. Valproatverordnungen bei Mädchen und Frauen im gebärfähigen Alter in Deutschland: Untersuchung zeitlicher Trends basierend auf Versichertendaten. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2018;61(8):1022-1029.
  • Wentzell N, Schink T, Haug U, Ulrich S, Niemeyer M, Mikolajczyk R. Optimizing an algorithm for the identification and classification of pregnancy outcomes in German claims data. Pharmacoepidemiology and Drug Safety. 2018;27(9):1005-1010.
  • Haug U, Grobbee EJ, Lansdorp-Vogelaar I, Spaander MCW, Kuipers EJ. Immunochemical faecal occult blood testing to screen for colorectal cancer: Can the screening interval be extended? Gut. 2017;66(7):1262-1267.
  • Zia Shams A, Haug U. Strategies for prevention of gastrointestinal cancers in developing countries: A systematic review. Journal of Global Health. 2017;7(2):020405.
  • Fiederling J, Zia Shams A, Haug U. Validity of self-reported family history of cancer: A systematic literature review on selected cancers. International Journal of Cancer. 2016;139(7):1449-1460.
  • Haug U, Becker N. Immunologische Stuhlbluttests zur Darmkrebsfrüherkennung: Schnelltests sind keine vertretbare Option für ein qualitätsgesichertes Programm. Deutsche Medizinische Wochenschrift. 2016;141(10):729-731.
  • Young GP, Senore C, Mandel JS, Allison JE, Atkin WS, Benamouzig R, Bossuyt P, De Silva M, Guittet L, Halloran SP, Haug U, Hoff G, Itzkowitz SH, Leja M, Levin B, Meijer GA, O'Morain CA, Parry S, Rabeneck L, Rozen P, Saito H, Schoen RE, Seaman HE, Steele RJC, Sung JJY, Winawer SJ. Recommendations for a step-wise comparative approach to the evaluation of new screening tests for colorectal cancer. Cancer. 2016;122(6):826-839.
  • Hermann S, Friedrich S, Haug U, Rohrmann S, Becker N, Kaaks R. Association between socio-economic and demographic characteristics and utilization of colonoscopy in the EPIC-Heidelberg cohort. European Journal of Cancer Prevention. 2015;24(2):81-88.
  • Fiederling J, Ulrich C, Hemminki K, Haug U. Consideration of family history of cancer in medical routine: A survey in the primary care setting in Germany. Eur J Cancer Prev. 2014;23(3):199-205.
  • Haug U, Engel S, Verheyen F, Linder R. Estimating colorectal cancer treatment costs: A pragmatic approach exemplified by health insurance data from Germany. PLOS ONE. 2014;9(2):e88407.
  • Haug U, Knudsen AB, Lansdorp-Vogelaar I, Kuntz KM. Development of new non-invasive tests for colorectal cancer screening: The relevance of information on adenoma detection. International Journal of Cancer. 2014;136(12):2864-2874.
  • Haug U, Rösch T, Hoffmeister M, Katalinic A, Brenner H, Becker N. Einführung eines organisierten Darmkrebs-Screenings in Deutschland: Chancen und Herausforderungen. Das Gesundheitswesen. 2014;77(11):869-874.
  • Ordonez-Mena JM, Schöttker B, Haug U, Muller H, Kohrle J, Schomburg L, Holleczek B, Brenner H. Serum 25-hydroxyvitamin D and cancer risk in older adults: Results from a large German prospective cohort study. Cancer Epidemiology, Biomarkers & Prevention. 2013;22(5):905-916.
  • Perna L, Butterbach K, Haug U, Schöttker B, Müller H, Arndt V, Holleczek B, Burwinkel B, Brenner H. Vitamin D receptor genotype rs731236 (Taq1) and breast cancer prognosis. Cancer Epidemiology, Biomarkers & Prevention. 2013;22(3):437-442.
  • Perna L, Felix JF, Breitling LP, Haug U, Raum E, Burwinkel B, Schöttker B, Brenner H. Genetic variations in the vitamin D binding protein and season-specific levels of vitamin D among older adults. Epidemiology. 2013;24(1):104-109.
  • Perna L, Hoffmeister M, Schöttker B, Arndt V, Haug U, Holleczek B, Burwinkel B, Ordonez-Mena JM, Brenner H. Vitamin D receptor polymorphism and colorectal cancer-specific and all-cause mortality. Cancer Epidemiology. 2013;37(6):905-907.
  • Schöttker B, Haug U, Schomburg L, Köhrle J, Perna L, Müller H, Holleczek B, Brenner H. Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study. The American Journal of Clinical Nutrition. 2013;97(4):782-793.
  • Bünger S, Haug U, Kelly M, Posorski N, Klempt-Giessing K, Cartwright A, Fitzgerald SP, Toner V, McAleer D, Gemoll T, Laubert T, Büning J, Fellermann K, Bruch H-P, Roblick UJ, Brenner H, von Eggeling F, Habermann JK. A novel multiplex-protein array for serum diagnostics of colon cancer: A case-control study. BMC Cancer. 2012;12:393.
  • Haug U, Knudsen AB, Kuntz KM. How should individuals with a false-positive fecal occult blood test for colorectal cancer be managed? A decision analysis. International Journal of Cancer. 2012;131(9):2094-2102.
  • Haug U, Poole EM, Xiao L, Curtin K, Duggan D, Makar KW, Peters U, Kulmacz RJ, Potter JD, Koepl L, Caan BJ, Slattery ML, Ulrich CM. Glutathione peroxidase tagSNPs: Associations with rectal cancer but not with colon cancer. Genes, Chromosomes & Cancer. 2012;51:598-605.
  • Perna L, Haug U, Schöttker B, Müller H, Raum E, Jansen E, Brenner H. Public health implications of standardized 25-hydroxyvitamin D levels: A decrease in the prevalence of vitamin D deficiency among older women in Germany. Preventive Medicine. 2012;55(3):228-232.
  • Schöttker B, Jansen EH, Haug U, Schomburg L, Köhrle J, Brenner H. Standardization of misleading immunoassay based 25-hydroxyvitamin D levels with liquid chromatography tandem-mass spectrometry in a large cohort study. PLOS ONE. 2012;7:e48774.
  • Stock C, Pulte D, Haug U, Brenner H. Subsite-specific colorectal cancer risk in the colorectal endoscopy era. Gastrointestinal Endoscopy. 2012;75(3):621-630.
  • Tao S, Haug U, Kuhn K, Brenner H. Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for non-invasive colorectal cancer screening. British Journal of Cancer. 2012;106(8):1424-1430.
  • Bünger S, Haug U, Kelly FM, Klempt-Giessing K, Cartwright A, Posorski N, Dibbelt L, Fitzgerald SP, Bruch H-P, Roblick UJ, von Eggeling F, Brenner H, Habermann JK, on behalf of the BMBF consortium "Colorectal Cancer Screening Chip". Toward standardized high-throughput serum diagnostics: Multiplex-protein array identifies IL-8 and VEGF as serum markers for colon cancer. Journal of Biomolecular Screening. 2011;16(9):1018-1026.
  • Haug U, Brenner H, Knudsen AB, Kuntz KM. Is fecal occult blood testing more sensitive for left- than for right-sided colorectal neoplasia? A systematic review. Expert Review of Molecular Diagnostics. 2011;11(6):605-616.
  • Haug U, Kuntz KM, Knudsen AB, Hundt S, Brenner H. Sensitivity of fecal occult blood testing for detecting left- vs right-sided advanced neoplasia. British Journal of Cancer. 2011;104:1779-1785.
  • Stock C, Knudsen AB, Lansdorp-Vogelaar I, Haug U, Brenner H. Colorectal cancer mortality prevented by use and attributable to nonuse of colonoscopy. Gastrointestinal Endoscopy. 2011;73(3):435-443.
  • Tao S, Hundt S, Haug U, Brenner H. Sensitivity of blood-based tests for colorectal cancer detection: Impact of overrepresentation of advanced stage disease. The American Journal of Gastroenterology. 2011;106(2):242-253.
  • Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: Circulating vitamin D and ovarian cancer risk. Gynecologic Oncology. 2011;121(2):369-375.
  • Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: Serum vitamin D and colorectal adenoma risk. Preventive Medicine. 2011;53(1-2):10-16.
  • Brenner H, Haug U, Arndt V, Stegmaier C, Altenhofen L, Hoffmeister M. Low risk of colorectal cancer and advanced adenomas more than 10 years after negative colonoscopy. Gastroenterology. 2010;138(3):870-876.
  • Brenner H, Haug U, Hundt S. Inter-test agreement and quantitative cross-validation of immunochromatographical fecal occult blood tests. International Journal of Cancer. 2010;127(7):1643-1649.
  • Brenner H, Haug U, Hundt S. Sex differences in performance of fecal occult blood testing. The American Journal of Gastroenterology. 2010;105(11):2457-2464.
  • Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L, Haug U. Protection from right- and left-sided colorectal neoplasms after colonoscopy: Population-based study. Journal of the National Cancer Institute. 2010;102(2):89-95. 10.1093/jnci/djp436
  • Brenner H, Tao S, Haug U. Low dose aspirin use and performance of immunochemical fecal occult blood tests. JAMA. 2010;304(22):2513-2520.
  • Haug U, Hundt S, Brenner H. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: Evaluation in the target population of screening and comparison with qualitative tests. The American Journal of Gastroenterology. 2010;105(3):682-690.
  • Hoffmeister M, Schmitz S, Karmrodt E, Stegmaier C, Haug U, Arndt V, Brenner H. Male sex and smoking have a larger impact on the prevalence of colorectal neoplasia than family history of colorectal cancer. Clinical Gastroenterology and Hepatology. 2010;8(10):870-876.
  • Sieverding M, Matterne U, Ciccarello L, Haug U. Colonoscopy use in a country with a long-standing colorectal cancer screening programme: Evidence from a large German survey. Zeitschrift für Gastroenterologie. 2010;48(12):1351-1357.
  • Stock C, Haug U, Brenner H. Population-based prevalence estimates of history of colonoscopy or sigmoidoscopy: review and analysis of recent trends. Gastrointestinal Endoscopy. 2010;71(2):366-381.
  • Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: Serum vitamin D and breast cancer risk. European Journal of Cancer. 2010;46(12):2196-2205.
  • Brenner H, Hoffmeister M, Brenner G, Altenhofen L, Haug U. Expected reduction of colorectal cancer incidence within 8 years after introduction of the German screening colonoscopy programme: Estimates based on 1,875,708 screening colonoscopies. European Journal of Cancer. 2009;45(11):2027-2033.
  • Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Annals of Internal Medicine. 2009;150(3):162-169.
  • Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: Longitudinal studies of serum vitamin D and colorectal cancer risk. Alimentary Pharmacology & Therapeutics. 2009;30(2):113-125.
  • Yin L, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. Cancer Epidemiology. 2009;33(6):435-445.
  • Brenner H, Hoffmeister M, Haug U. Family history and age at initiation of colorectal cancer screening. The American Journal of Gastroenterology. 2008;103(9):2326-2331.
  • Brenner H, Hooffmeister M, Haug U. Should colorectal cancer screening start at the same age in European countries? Contributions from descriptive epidemiology. British Journal of Cancer. 2008;99(3):532-535.
  • Haug U, Hundt S, Brenner H. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. British Journal of Cancer. 2008;99(1):133-135.
  • Haug U, Wente M, Seiler CM, Jesnowski R, Brenner H. Stool testing for the early detection of pancreatic cancer: Rationale and current evidence. Expert Review of Molecular Diagnostics. 2008;8(6):753-759.
  • Müller H, Haug U, Rothenbacher D, Stegmaier C, Brenner H. Evaluation of serum and urinary myeloid related protein-14 as a marker for early detection of prostate cancer. The Journal of Urology. 2008;180(4):1309-1313.
  • Brenner H, Hoffmeister M, Arndt V, Haug U. Gender differences in colorectal cancer: Implications for age at initiation of screening. British Journal of Cancer. 2007;96(5):828-831.
  • Brenner H, Hoffmeister M, Stegmaier C, Brenner G, Altenhofen L, Haug U. Risk of progression of advanced adenomas to colorectal cancer by age and sex: Estimates based on 840,149 screening colonoscopies. Gut. 2007;56(11):1585-1589.
  • Haug U, Hillebrand T, Bendzko P, Low M, Rothenbacher D, Stegmaier C, Brenner H. Mutant-enriched PCR and allele-specific hybridization reaction to detect K-ras mutations in stool DNA: High prevalence in a large sample of older adults. Clinical Chemistry. 2007;53(4):787-790.
  • Haug U, Rothenbacher D, Wente MN, Seiler CM, Stegmaier C, Brenner H. Tumour M2-PK as a stool marker for colorectal cancer: Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. British Journal of Cancer. 2007;96(9):1329-1334.
  • Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: A systematic review. Cancer Epidemiology, Biomarkers & Prevention. 2007;16(10):1935-1953.
  • Haug U, Wente MN, Seiler CM, Rothenbacher D, Buchler MW, Brenner H. Tumor-M2-PK as a stool marker for colorectal cancer: Stability at room temperature and implications for application in the screening setting. Clinical Chemistry. 2006;52(4):782-784.
  • Haug U, Brenner H. New stool tests for colorectal cancer screening: A systematic review focusing on performance characteristics and practicalness. International Journal of Cancer. 2005;117(2):169-176.
  • Haug U, Brenner H. A simulation model for colorectal cancer screening: Potential of stool tests with various performance characteristics compared to screening colonoscopy. Cancer Epidemiology, Biomarkers & Prevention. 2005;14(2):422-428.
  • Editorials

  • Haug U, Pigeot I. Krebsfrüherkennung: Ja oder Nein? Facetten einer komplexen Antwort. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2018;61(12):1481-1483.
  • Haug U. Flexible sigmoidoscopy screening for colorectal cancer. The BMJ. 2017;356:j75.
  • Position Papers

  • Deutsche Gesellschaft für Epidemiologie (DGEpi), in collaboration with Haug U, Hense H-W, Twardella D. Stellungnahme zum Beschlussentwurf des G-BA: Richtlinie für organisierte Krebsfrüherkennungsprogramme und Änderung der Krebsfrüherkennungs-Richtlinie. 2018;
  • Editorships

  • Pigeot I, Haug U. Stand der Krebsfrüherkennung in Deutschland. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 61(12). Springer. 2018.
  • Contributions to books and proceedings

  • Haug U. Screening des kolorektalen Karzinoms. In: Schmoll H-J, editors. Kompendium internistische Onkologie. 5. Auflage. Berlin, Heidelberg: Springer. 2021.
  • Commentaries

  • Haug U, Senore C, Corley D. Promises and potential pitfalls of shared decision-making in cancer screening. Gastroenterology. 2020;158(4):802-805.
  • Senore C, Haug U. Faecal immunochemical tests have the potential for correctly ruling out colorectal cancer in symptomatic patients. BMJ Evidence-Based Medicine. 2018;23(3):113-114.

For further publications please follow this link:

Prizes and awards

  • Vision Zero Präventionsaward 2020
    Network against cancer (2020)
    Outstanding achievements in the field of colorectal cancer prevention and screening
  • Mitglied von / Member of
    AcademiaNet – Expert Database of Outstanding Women in Science (2017)
  • Darmkrebs-Präventionspreis 2016 / Colorectal Cancer Prevention Award 2016
    German Cancer Society (2016)
  • Reisestipendium (travel grant) “Best submitted abstracts” / Oral Free Paper Prize
    United European Gastroenterology Week (2014)
  • Felix-Burda-Award for Medical Prevention
  • Young Scientist Award (1st prize) of the German Epidemiological Association
    German Epidemiological Association (2005)
  • Promotionsstipendium 2002-2005 / PhD scholarship
    DFG (2002)


  • Master in Epidemiology at the University of Bremen
  • Bachelor in Public Health at the University of Bremen

The responsibility for the content of this page lies with Ulrike Haug.